Beyond Meat Earnings Call Transcripts
Fiscal Year 2026
-
The meeting saw the election of three directors, ratification of the auditor, and rejection of the executive compensation proposal. Management addressed shareholder concerns on product strategy, sustainability, and share value, outlining plans for core product focus and innovation through new platforms.
-
Q1 2026 saw net revenues decline 15.3% year-over-year to $58.2 million, but gross margin and net loss improved significantly due to cost controls and operational efficiencies. Expansion into functional beverages and new product launches aim to offset ongoing category headwinds.
Fiscal Year 2025
-
Q4 2025 saw a 19.7% revenue decline and a net income boost from debt restructuring, amid weak demand and major non-routine charges. The company is pivoting to adjacent categories, launching a new beverage line, and focusing on cost control and operational efficiency.
-
Stockholders approved four key proposals, including new convertible notes, equity plan expansion, a major increase in authorized shares, and a reverse stock split. Management addressed questions on the reverse split and reaffirmed strategic commitment.
-
Q3 2025 saw a 13% revenue decline and a net loss of $110.7 million, with gross margin dropping to 10.3%. Major debt reduction and new capital raised have reset the balance sheet, while the company focuses on operational efficiency, margin recovery, and product innovation.
-
Q2 2025 net revenue fell 20% year-over-year to $75M, with gross margin down to 11.5% and a net loss of $33.2M. Management is accelerating cost reductions, restructuring operations, and focusing on margin expansion, while guiding Q3 revenue to $68–$73M amid ongoing category softness.
-
The meeting covered director elections, auditor ratification, and executive compensation approval. Management addressed shareholder questions on compensation, product marketing, sustainability, and new product ideas, reaffirming a commitment to transparency and innovation.
-
Q1 2025 saw a 9.1% revenue decline and negative gross margin, driven by U.S. distribution gaps and weak demand. Management withdrew full-year guidance, focusing on cost control, margin recovery, and new financing to support a path to EBITDA positive by end of 2026.
Fiscal Year 2024
-
Year-over-year net revenue growth returned in the second half of 2024, with Q4 revenues up 4% and significant cost reductions driving a nearly $100 million improvement in adjusted EBITDA. 2025 guidance targets flat to modest revenue growth, a 20% gross margin, and further operating expense cuts, with a strategic focus on achieving EBITDA-positive operations by end of 2026.
-
Q3 2024 saw a return to year-over-year revenue growth, gross margin expansion to 17.7%, and significant reductions in operating expenses and net loss. Product innovation and premium positioning drove performance, with positive outlook for continued margin improvement and liquidity actions ahead.
-
Q2 2024 saw net revenues of $93.2M, exceeding guidance but down 8.8% year-over-year, with gross margin rising to 14.7%. Operating expenses and cash use declined sharply, while the Beyond IV product line launch and cost initiatives drove margin gains. Full-year guidance was raised, with further margin improvement expected.